Strategies for delivering therapeutics across the blood–brain barrier
One
Our knowledge of its pharmacokinetics in the brain and, in particular
We investigated the effects of prednisone, 80 mg/day for five days, on the ratio of cerebrospinal fluid (CSF) albumin/serum albumin, a measure of blood-brain barrier
Preventive treatment with high-dose methylprednisolone attenuated the systemic inflammatory response to open-heart surgery with cardiopulmonary bypass, but did not prevent or attenuate the increase in BBB permeability or the neuroinflammatory response
A "rebound" of transmigration at Learn about steroids for MS, such as Solu-Medrol and prednisone
Nanoparticles that have advantage of the assembly at the nanoscale of available biomaterials can provide a delivery platform with potential to raising brain levels of either imaging therapeutic drugs or imaging
DOI: 10
Development of a safe and effective BBB modulator would revolutionise the treatment of CNS diseases and future drug development in the area
Methylprednisolone treatment in brain death-induced lung inflammation-a dose comparative study in rats
Hence, chemotherapy has had a limited role in the Objectives: Our previous experiments proved that methylprednisolone (MP) can significantly reduce axonal impairment accompanying extracellular oedema induced by the osmotic challenge (load) on the blood-brain barrier (BBB)
The blood-brain barrier (BBB) is composed of specific tight junction proteins and transporters expressed on the lining of endothelial cells of the vasculature in the brain
Gadolinium (Gd) enhancement of brain lesions by MRI is a marker of active blood-brain barrier damage secondary to an inflammatory process
The blood–brain barrier is a perennial challenge for the delivery of therapeutics to the central nervous system